Radiat Oncol J.
2013 Mar;31(1):18-24. 10.3857/roj.2013.31.1.18.
Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer
- Affiliations
-
- 1Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea. wuhg@snu.ac.kr
- 2Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
- 3Institute of Radiation Medicine, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea.
- 4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
- KMID: 1842028
- DOI: http://doi.org/10.3857/roj.2013.31.1.18
Abstract
- PURPOSE
The purpose of this study was to assess the clinical outcomes of hypofractionated radiotherapy (HFRT) with three-dimensional conformal technique for medically inoperable patients with early stage non-small-cell lung cancer (NSCLC) and to evaluate prognostic factors.
MATERIALS AND METHODS
We performed a retrospective review of 26 patients who underwent HFRT for early stage NSCLC between September 2005 and August 2011. Only clinical stage T1-3N0 was included. The median RT dose was 70 Gy (range, 60 to 72 Gy) and the median biologically equivalent dose (BED) was 94.5 Gy (range, 78.0 to 100.8 Gy). In 84.6% of patients, 4 Gy per fraction was used. Neoadjuvant chemotherapy with paclitaxel and cisplatin was given to 2 of 26 patients.
RESULTS
The median follow-up time for surviving patients was 21 months (range, 13 to 49 months). The overall response rate was 53.9%, and the initial local control rate was 100%. The median survival duration was 27.8 months. Rates of 2-year overall survival, progression-free survival (PFS), local control (LC), and locoregional-free survival (LRFS) were 54.3%, 61.1%, 74.6%, and 61.9%, respectively. Multivariate analysis showed that BED (>90 vs. < or =90 Gy) was an independent prognostic factor influencing PFS, LC, and LRFS. Severe toxicities over grade 3 were not observed.
CONCLUSION
Radical HFRT can yield satisfactory disease control with acceptable rates of toxicities in medically inoperable patients with early stage NSCLC. HFRT is a viable alternative for clinics and patients ineligible for stereotactic ablative radiotherapy. BED over 90 Gy and 4 Gy per fraction might be appropriate for HFRT.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Stereotactic radiotherapy for early stage non-small cell lung cancer
- Definitive Radiotherapy of Non-Small Cell Lung Cancer
- Stereotactic Body Radiotherapy for Early Stage Lung Cancer
- The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing Paradigms
- Moderate hypofractionated image-guided thoracic radiotherapy for locally advanced node-positive non-small cell lung cancer patients with very limited lung function: a case report
